Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

What Was Tested

The paper reports a study of CGRP (Calcitonin Gene-Related Peptide) in the context of migraine, published as a randomized controlled trial.

ClinicalTrials.gov identifiers: HALO CM: NCT02621931 ; HALO EM: NCT02629861 ; FOCUS: NCT03308968 .

Who Took Part

PubMed indexes the participants as older adults.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this CGRP (Calcitonin Gene-Related Peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received CGRP (Calcitonin Gene-Related Peptide).

Some participants received a placebo instead of CGRP (Calcitonin Gene-Related Peptide), giving a reference point.

What Was Measured

PubMed files the paper under topics including Antibodies, Monoclonal, Calcitonin Gene-Related Peptide and Migraine Disorders.

Author keywords: CGRP, Chronic migraine, Episodic migraine, Fremanezumab and Older age.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of CGRP (Calcitonin Gene-Related Peptide) in people with migraine.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (The journal of headache and pain), a journal based in England.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.